circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggregate of 62,850 shares of common stock to six new employees whose employment commenced in November 2020 as
Toggle Summary Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum
Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting SOUTH SAN FRANCISCO, Calif. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced additional results from GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes
Toggle Summary Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in virtual fireside chats at the Piper Sandler 32 nd Annual Healthcare Conference taking
Toggle Summary Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen
Company Committed to Advancing Omecamtiv   Mecarbil with Initial Focus on Preparation s   for Regulatory Interaction s Following Positive Results of GALACTIC-HF Company to Host Conference Call and Webcast Today at 8:30   AM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov.

EVENTS